On February 18, 2022 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, developing transformative therapies for patients with cancer and autoimmune diseases, reported Memorial Sloan Kettering Cancer Center’s (MSK) notification to the U.S. Food and Drug Administration (FDA) of a fatal serious adverse event (SAE) associated with a patient treated in the ongoing Phase 1, MSK-conducted dose-escalation clinical study of autologous mesothelin CAR T, ATA2271 (Press release, Atara Biotherapeutics, FEB 18, 2022, View Source [SID1234608314]). MSK has voluntarily paused enrollment of new patients in the study on a temporary basis while additional information regarding the case is gathered and reviewed. The FDA has notified MSK of its agreement with this approach.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ATA2271 is a next-generation, autologous chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin currently under clinical investigation in patients with malignant pleural mesothelioma. The single case involved a patient with a history of multiple malignancies and other comorbidities undergoing treatment for advanced recurrent mesothelioma. MSK is in the process of further evaluating the occurrence, including the extent of the relationship of the event to ATA2271.

"The safety of every patient participating in studies we are funding or conducting is of the utmost priority for Atara," said Jakob Dupont, MD, Head of Global Research & Development at Atara. "Clinical evaluation of the case remains ongoing, and we are working closely with investigators at MSK, who are conducting the ATA2271 study under their IND, to establish the underlying causes of the event. We anticipate providing a further update in the coming weeks following further discussion and consultation with MSK."

The median survival of treated patients with malignant pleural mesothelioma is 9-17 months even with successful completion of a combination of chemotherapy, aggressive surgical resection, and radiation therapy. The first six patients enrolled in the two lowest dose cohorts received either 1×106 cells/kg (patients 1-3) or 3×106 cells/kg (patient 4-6) intrapleural ATA2271. Within these two cohorts, no dose limiting toxicities have been reported to date. The patient event being reported relates to the first patient in a third, higher-dose cohort (6×106 cells/kg).

The temporary pause in ATA2271 study enrollment does not impact the IND-enabling work currently underway to advance ATA3271, a separate, off-the-shelf, allogeneic CAR-T therapy targeting mesothelin using next-generation PD1DNR and 1XX CAR technologies for patients with advanced mesothelioma. ATA3271, ATA3219, tab-cel, and ATA188 all utilize Atara’s allogeneic EBV T-cell platform, the safety and tolerability of which has been validated by clinical studies and experience in approximately 400 patients in various disease areas with no observed cytokine release syndrome (CRS) to date.

MSK Disclosure: MSK has intellectual property rights and associated interests by virtue of licensing agreements between MSK and Atara.

On February 18, 2022 The board of directors of Abbott (NYSE: ABT) reported a quarterly common dividend of 47 cents per share (Press release, Abbott, FEB 18, 2022, View Source [SID1234608313]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abbott has increased its dividend payout for 50 consecutive years.
This marks the 393rd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 16, 2022, to shareholders of record at the close of business on April 15, 2022.

Abbott has increased its dividend payout for 50 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.

On February 18, 2022 Recipharm, a leading global contract development and manufacturing organisation (CDMO), reported the acquisition of Arranta Bio, a prominent advanced therapy CDMO (Press release, Recipharm, FEB 18, 2022, View Source [SID1234608312]). Under the stewardship of Mark Bamforth and backed by Ampersand Capital Partners, the company has established a strong service portfolio as a leader in delivering microbiome therapeutic products and mRNA clinical production capabilities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The acquisition forms a cornerstone of Recipharm’s strategy to provide innovative drug developers in the Biologics market with scientifically differentiated contract development and manufacturing services for ATMPs and builds on the capabilities acquired through the recently announced GenIbet transaction and the acquisition of Vibalogics, also announced today.

Arranta Bio has established a strong microbiome platform with fermentation and purification expertise for naturally-derived and engineered bacteria consortia, complemented by services in analytics, proprietary media and cryopreservative formulations. These services maximize yields and enhance viability for live biotherapeutic products that clients are testing in the clinic against a range of infectious, inflammatory, neurological and oncological diseases.

In addition, Arranta Bio is progressing the supply of end-to-end mRNA capabilities across drug substance and drug product under one roof, providing its customers with substantial time savings in product manufacturing and a hedge against supply chain challenges.

The acquisition of Arranta establishes a robust US presence for Recipharm. It provides the company with a further platform from which to build its capabilities in new biologics modalities, leveraging Arranta’s expertise in advanced therapies to bring a high degree of diversification across multiple technologies and modalities.

Marc Funk, Chief Executive Officer at Recipharm, said: "We welcome Arranta and its team of experts who boast a strong reputation in the CDMO industry. Arranta is a leading player in its field that we are proud of bringing under the Recipharm umbrella and continue to build in line with our vision of supporting biotechs by providing process development, manufacturing expertise and bold solutions to take their programs from lab to patient.

This acquisition is another important step for us in growing our biologics business and developing a strong presence into the US. We look forward to working closely with the Arranta team, building links across the wider Recipharm organisation to make this business a huge success."

Mark Bamforth, CEO at Arranta, added: "I am convinced that Recipharm will be a great home for Arranta and our talented team and that together we can fulfil our joint vision of building the leading ATMP CDMO. We share Recipharm’s vision of focusing on ATMP customers with novel manufacturing solutions and we see a clear opportunity to accelerate to global scale in this new context."

The acquisition is expected to be completed around the end of March 2022, subject to customary regulatory filings.

Centerview Partners UK LLP acted as exclusive financial adviser, and Kirkland & Ellis LLP served as counsel to Recipharm on the transaction. Morgan Stanley & Co. LLC acted as exclusive financial adviser and Goodwin Procter LLP served as counsel to Arranta Bio.

On February 18, 2022 Minomic reported that it will be at the ASCO (Free ASCO Whitepaper) GU Symposium, San Francisco, where Dr Neal Shore, principal investigator, is presenting a poster on our study "MiCheck Prostate Blood Test for Aggressive Prostate Cancer Designed for the Clinical Lab Setting" (Press release, Minomic, FEB 18, 2022, View Source [SID1234608310]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Our poster will be displayed on Thursday Feb 17 at 11.30am Megan Henken will be there live and Doug Campbell and Brad Walsh will be joining online.

On February 17, 2022 Blue Water Vaccines, Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), a biopharmaceutical company developing vaccines, reported the pricing of its initial public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share (Press release, Onconetix, FEB 17, 2022, View Source [SID1234641103]). The shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol "BWV" on February 18, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The aggregate gross proceeds to BWV from the initial public offering are expected to be approximately $20 million prior to deducting underwriting discounts, commissions, and other estimated offering expenses. The offering is expected to close on February 23, 2022, subject to the satisfaction of customary closing conditions.

Boustead Securities, LLC is acting as the sole book-running manager for the offering.

The Securities and Exchange Commission ("SEC") declared effective a registration statement on Form S-1 relating to these securities on February 11, 2022. A final prospectus relating to this offering will be filed with the SEC. The offering is being made only by means of a prospectus, copies of which, when available, may be obtained from; Boustead Securities, LLC, Attention: Prospectus Department, 6 Venture, Suite 325, Irvine, CA 92618, or by telephone at 949-502-4408, or by email at [email protected]. Investors may also obtain these documents at no cost by visiting the SEC’s website at View Source

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.